What is the clinical evidence from this study?

Study design: Observational. Population: Patients over 75 years old with heart failure with preserved ejection fraction (HFpEF), LVEF > 50%, NYHA class II-IV, stable heart failure with elevated natriuretic peptides (n=215). Intervention: Dapagliflozin vs. Standard treatment without dapagliflozin. Primary outcome: Kansas City Cardiomyopathy Questionnaire Overall Summary Score (KCCQ OSS) improvement (p = 0.027, p=0.027).

What question did this study set out to answer?

This study aims to evaluate the efficacy and safety of dapagliflozin in patients over 75 years with heart failure with preserved ejection fraction.

March 2, 2026Open Access

Efficacy and Safety of Dapagliflozin in Patients Over 75 Years Old With Heart Failure With Preserved Ejection Fraction: A Retrospective Study

Key Result

Dapagliflozin plus standard therapy improved KCCQ Overall Summary Score to 72.48±12.49 versus 68.59±13.11 in control, p = 0.027 in patients >75 with HFpEF after 12 weeks.

Key Points

This study aims to evaluate the efficacy and safety of dapagliflozin in patients over 75 years with heart failure with preserved ejection fraction.
Retrospective analysis of HFpEF patients aged over 75
Assessment of cardiac function and exercise capacity improvements
Evaluation of quality of life markers
Dapagliflozin significantly enhances cardiac function
Increase in exercise capacity observed
Improvement in quality of life markers noted
No notable safety concerns reported

Study Design

Type

Observational (n=215)

Multicenter

Structured PICO

Does dapagliflozin improve KCCQ scores, exercise capacity, and cardiac function in patients over 75 years old with HFpEF?

Population

215 patients over 75 years old with HFpEF (LVEF > 50%, NYHA II-IV), mean age ~80, ~54% male, based in China. Key inclusion: stable history of heart failure (no hospitalization within 3 months), evidence of structural heart disease, and elevated natriuretic peptides (NT-proBNP ≥225 pg/mL or BNP ≥75 pg/mL).

Intervention

Dapagliflozin 10 mg oral once daily added to standard therapy for 12 weeks.

Comparator

Standard therapy alone (routine group) including ACEi/ARB/ARNI, beta-blockers, loop diuretics, and MRAs.

Outcome

Kansas City Cardiomyopathy Questionnaire (KCCQ) scores and Six-Minute Walk Test (6MWT) distance at 12 weeks.patient reported

Main Result

Effect estimate: p = 0.027

Absolute Event Rate: 72.48% vs 68.59%

p-value: p=0.027

Limitations

Retrospective observational design limits causality inference
Single-center study limits generalizability
Short follow-up duration of 12 weeks
Potential for unmeasured confounding factors

Abstract

Dapagliflozin administration in HFpEF patients over 75 years significantly enhances cardiac function and exercise capacity, as well as improves quality of life markers, without notable safety concerns.

Bookmark

View Full Paper

Bookmark

View Full Paper

Cite This Study

Wang et al. (Thu,) conducted a observational in Patients over 75 years old with heart failure with preserved ejection fraction (HFpEF), LVEF > 50%, NYHA class II-IV, stable heart failure with elevated natriuretic peptides (n=215). Dapagliflozin vs. Standard treatment without dapagliflozin was evaluated on Kansas City Cardiomyopathy Questionnaire Overall Summary Score (KCCQ OSS) improvement (p = 0.027, p=0.027). Dapagliflozin plus standard therapy improved KCCQ Overall Summary Score to 72.48±12.49 versus 68.59±13.11 in control, p = 0.027 in patients >75 with HFpEF after 12 weeks.

synapsesocial.com/papers/69a52e64f1e85e5c73bf216b https://doi.org/https://doi.org/10.31083/bjhm50721